Summary We undertook the present study to clarify the molecular mechanism of the effect of a new anti-cancer drug, vesnarinone, on a human salivary gland cancer cell line, TYS. We isolated TSC-22 cDNA as a vesnarinone-inducible gene from a cDNA library constructed from vesnarinone-treated TYS cells. TSC-22 was originally reported as a transforming growth factor (TGF)-,-inducible gene. The expression of TSC-22 was up-regulated within a few hours after treatment with vesnarinone and was continued for 3 days. The level of TSC-22 mRNA in TYS cells was continuously increased until the cells reached confluency. Furthermore, the induction of TSC-22 by vesnarinone was inhibited by treatment with cycloheximide. When we treated the cells with an antisense oligonucleotide against TSC-22 mRNA under quiescent conditions, the antisense oligonucleotide stimulated the growth of TYS cells; however, under growing conditions the antisense oligonucleotide did not affect cell growth. Furthermore, the antisense oligonucleotide suppressed the antiproliferative effect of vesnarinone. These results suggest that TSC-22 may be a negative growth regulator and may play an important role in the antiproliferative effect of vesnarinone.
Vesnarinone (3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl) -1-piperazinyl]-2(1H)-quinolinone) was originally developed as an oral inotropic agent and has been used for the treatment of chronic heart failure in Japan (Asanoi et al, 1987) . It has been reported recently that vesnarinone has an antiproliferative and differentiation-and apoptosis-inducing activity in several tumour cells in vitro and in vivo (Sato et al, 1994 (Sato et al, , 1995 . Therefore, vesnarinone has been subjected to a clinical phase study as an anti-cancer drug in the treatment of several solid tumours, including head and neck cancer, in Japan. We have recently reported the up-regulation of TGF-J1 and p21tafJ mRNA and their proteins in a human salivary gland cancer cell line after treatment with vesnarinone (Sato et al, 1997) . However, the molecular mechanism of the antiproliferative effect of vesnarinone is not fully understood.
A human salivary gland cancer cell line, TYS, was established in our laboratory (Yanagawa et al, 1986) . We have shown that vesnarinone markedly inhibits the growth of TYS cells in vitro and in vivo (Sato et al, 1994 (Sato et al, , 1995 . In this study, we attempted to clarify the molecular mechanism of the effect of vesnarinone on TYS cells. We isolated TSC-22 cDNA as a vesnarinone-inducible gene by a random sequencing method. TSC-22 was reported as a transforming growth factor (TGF)-p or follicle-stimulating hormone (FSH) inducible transcriptional regulator containing a leucine zipper-like structure in mice (Shibanuma et al, 1992) , rats (Hamil and Hall, 1994) and humans (Jay et al, 1996) . We examined the expression of TSC-22 mRNA in detail in vesnarinonetreated or untreated TYS cells. Furthermore, we tested the effect of an antisense oligonucleotide against human TSC-22 mRNA on vesnarinone-treated or untreated TYS cells. Received 18 March 1997 Revised 10 June 1997 Accepted 11 June 1997 Correspondence to: H Kawamata MATERIALS AND METHODS Cell culture TYS cells were grown in Dulbecco's modified eagle medium (DMEM; Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS; Bio-Whittaker, Walkersville, MD, USA), 100,g ml' streptomycin, 100 U ml-' penicillin (Gibco) and 0.25 ,ug ml' amphotericin B (Gibco) in a humidified atmosphere of 95% air and 5% carbon dioxide at 37°C.
Treatment of the cells with vesnarinone
Vesnarinone was kindly provided by Otsuka Pharmaceutical Company, Tokyo. Vesnarinone was dissolved in DMSO (Sigma, St Louis, MO, USA) at a concentration of 10 mg ml-' as a first stock solution and then the first stock solution was diluted with the complete culture medium described above to the desired concentration (0, 0.1, 1, 10, 50,g ml-'). The antiproliferative activity of vesnarinone stored in the medium was stable for at least 1 month at 4°C (data not shown). We evaluated the in vitro antiproliferative effect of vesnarinone on cancer cells using MTh [3-(3,4-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Carmichael et al, 1987) . Cells were seeded on 96-well plates (Falcon; Becton Dickinson Labware, Lincoln Park, NJ, USA) at 2 x 103 cells per well in DMEM containing 10% FCS. After 24 h, cells were placed in DMEM containing 10% FCS with several concentrations of vesnarinone (0, 0.1, 1, 10 and 50,g ml-'). After 2 and 4 days, the number of cells was quantitated by an assay using MIT (Sigma).
Cell cycle analysis TYS cells were cultured in the presence or absence of 50 gg ml' of vesnarinone for 24 h, 48 h and 72 h, and the cells were collected in conical tubes (Falcon). Then, the cells were fixed with 70% ethanol and washed with phosphate-buffered saline. After treatment with 100 gg ml-' of RNaseA (Sigma), the cells were stained with 40 ,ug ml-' propidium iodide (Molecular probes, Eugene, OR, USA), and the cell cycle was analysed by a digital flow cytometry system EPICS (Coulter, Miami, FL, USA).
RNA isolation
Total cytoplasmic RNA was prepared by lysing cells in hypotonic buffer containing Nonidet p-40 (Sigma), followed by removal of the nuclei. Poly(A)+ RNA was prepared from total cytoplasmic RNA using two cycles of oligo(dT)-cellulose chromatography.
Construction of cDNA library
Five micrograms of poly(A)+ RNA, which was isolated from TYS cells treated with vesnarinone (50 ,ug ml-') for 3 days and was reverse transcribed with Moloney-murine leukaemia virus reverse transcriptase (M-MLV) (Gibco) using oligo(dT)-Xhol primer/linker (Stratagene, La Jolla, CA, USA). Second-strand cDNA was synthesized using a cDNA synthesis kit purchased from Stratagene and ligated with the EcoRI adapter according to the manufacturer's recommendations. After XhoI digestion of the synthesized cDNA, the cDNA was ligated with the cloning vector ZAP Express (Stratagene), which had been digested with EcoRI and Sall. The cDNA was then inserted in antisense orientation from eukaryotic and prokaryotic promoter in the vector. A primary cDNA library contained about 1.5 x 105 independent clones and was 90% recombinant. The ZAP Express library was used after one round of amplification.
Random sequencing Randomly selected pBK-CMV library-transformed colonies were picked up by tooth pick and cultured overnight in 6 ml of LB medium containing 50 jg ml-' kanamycin. The phagemid was extracted by the alkaline lysis method and half of the phagemid was digested with EcoRI and PstI to excise the cDNA inserts. Most inserts ranged in size from 0.5 kb to 2.0 kb. The cDNA inserts were purified from agarose gel by Gene Clean kit II (Bio 101, Vista, CA, USA) and subsequently used as a probe for Northern blot analysis. The remaining half of the phagemid was subjected to sequencing analysis. DNA sequence was determined by the dideoxy chain-termination method using FITC-labelled primers and Takara promoter sequence (5'-taatacgactcactataggg-3'), which should be located up-stream of the cDNA inserts in the vector. Subsequently, the PCR products were subjected to the second-round PCR. The primers used for the second-round PCR were DP2 (5'-tctgcagctgggcctgaaactgggc-3'), which is located 7 bp upstream of DPI primer and contains the PstI site, and mUP (5'-atctagtttgaaccaggctg-3'), whose sequence is obtained from mouse and rat TSC-22 sequence 92 bp upstream from the translation initiation codon of TSC-22 in mouse or 84 bp upstream in rat (Shibanuma et al, 1992; Hamil and Hall, 1994) . The second-round PCR product containing human TSC-22-5' end was subcloned into pUCJ9
vector (pUCJ9-hTSC-22-5' end). PstI-digested hTSC-22-3' end fragment from pBK-CMV-hTSC-22-3' end was ligated into the pUCJ9-hTSC-22-5'end, which was predigested with PstI. Nearly full-length human TSC-22 cDNA was isolated at this point.
Northern blot analysis
Cytoplasmic RNA (20 jg) was electrophoresed onto a formaldehyde/1.0% agarose gel and blotted onto a nylon filter (Hybond N+; Amersham). The nylon filter was hybridized with 32P-labelled cDNA probes in 50% formamide, 5 x saline-sodium phosphate-EDTA, 0.1% sodium sulphate dodecyl (SDS), 5 x Denhardt's solution and 100 jig ml-' salmon sperm DNA at 42'C for 15-20 h.
Extensive washing was performed: twice with 0.1 x standard saline citrate-0.5% SDS at room temperature and once at 50°C for 40 min with the same washing buffer. Subsequently, the filter was exposed to radiographic film with an intensifying screen at -70°C. The probes used were a 1.2-kb 3' end of human TSC-22 cDNA, an 875-bp fragment of human p2Jwafl cDNA isolated in our laboratory (Sato et al, 1997) After washing with phosphate-buffered saline, HRP-conjugated goat anti-rabbit IgG (Amersham; 1:500) was added to the wells and incubated for 1 h at room temperature. Then, 100 ,ul of TMB (3,3',5,5'-tetramethylbenzidine; Sigma, 0.1 mg ml-1) solution was added to the wells followed by incubation for 10 min. The reaction was stopped using 50 ,ul (Figure 2 and Table 1 ). In the vesnarinonetreated group, the proportion of the cells at S and G2/M phase 24 h after addition of the drug was much lower than that in the control group ( Figure 2 and Table 1 ). After more than 48 h of exposure to vesnarinone, most of the TYS cells were arrested at G1 phase ( Figure 2 and Table 1 (Figure 3) . Furthermore, the TSC-22 mRNA expression in TYS cells was markedly enhanced by treatment with 50 jg ml-vesnarinone (225% of control at day 1, 164% of control at day 2 and 125% of control at day 3) (Figure 3 ). The induction of TSC-22 mRNA was continued for at least 3 days after the addition of the drug. We have already reported the up-regulation by vesnarinone of TGF-PJ and p2Iwafl mRNA and protein in TYS cells, and the growth-inhibitory effect of TGF-P1 on TYS cells (Sato et al, 1997) . We therefore, analysed the short time-course induction of TSC-22 by vesnarinone and TGF-f31. As shown in Figure 4 , the expression of TSC-22 was slightly enhanced by vesnarinone in a few hours, however marked induction of TSC-22 mRNA was observed at 24 h after the addition of vesnarinone. In contrast, very rapid induction of TSC-22 mRNA was observed after treatment with TGF-31 (Figure 4 ). To clarify whether or not the induction of TSC-22 and p2Jwafl mRNA was a direct effect of vesnarinone, we examined the effect of a protein synthesis inhibitor, cycloheximide, on the induction of the genes. The expression of TSC-22 mRNA was markedly enhanced by treatment with 10 gg ml-1 cycloheximide, probably as a result of accumulation of mRNA; however, induction of the TSC-22 gene by vesnarinone was inhibited by treatment with cycloheximide ( Figure 5 ). In contrast, the induction of p2lwafl by vesnarinone was not inhibited by treatment with cycloheximide ( Figure 5 ). These results indicate that the induction of TSC-22 mRNA by vesnarinone in TYS cells is mediated mainly by the production of proteins and that the induction of p2lwafl is a direct effect of vesnarinone.
Detection of TSC-22 protein
We detected two bands of TSC-22 protein at 20 kDa and 18 kDa using Western blotting ( Figure 6A Figure 6B ).
British Journal of Cancer (1998) (Figure 7) . However, treatment with an antisense oligonucleotide at the same concentration stimulated the growth of TYS cells (Figure 7 , P<0.01; one-factor analysis of variance). Furthermore, the antisense oligonucleotide suppressed the antiproliferative effect of vesnarinone on TYS cells (Figure 7) . In this experiment, the treatment of TYS cells with vesnarinone was started when the cells reached confluence, therefore the antiproliferative effect of vesnarinone against TYS cells was not as strong as that shown in Figure 1 . In contrast, when we treated the TYS cells with the antisense oligonucleotide in the presence or absence of vesnarinone under low-density culture conditions (2 x 103 per well), we could not demonstrate the clear effect of the antisense oligonucleotide (data not shown). As shown in Figure 3 , the expression of TSC-22 mRNA in TYS cells was very low under a low-density culture conditions but gradually increased until the cells reached confluence. Therefore, the antisense oligonucleotide was not effective under low-density culture conditions but was effective under highdensity culture conditions. British Journal of Cancer (1998) (Shibanuma et al, 1992; Hamil and Hall, 1994; Jay et al, 1996) This high amino acid sequence conservation beyond the species indicates an essential role of TSC-22 in regulating cellular activities such as cell growth, differentiation and apoptosis. We detected 18-kDa and 20-kDa proteins in TYS cells by Western blotting using a specific antibody against recombinant human TSC-22 protein. Thus, the TSC-22 gene may produce the functional protein and may in fact regulate cell growth. The mRNA expression of TSC-22 was slightly enhanced by vesnarinone in a few hours; however, apparent induction of TSC-22 mRNA was observed 24 h after the addition of vesnarinone and continued for at least 3 days. In contrast, very rapid induction of TSC-22 mRNA was observed after treatment with TGF-,B I in TYS cells. Shibanuma et al (1992) and Hamil and Hall (1994) reported that the induction of TSC-22 in mouse and rat cells by TGF-,13 or FSH was rapid but transient, similar to that of Jun and Fos. We have reported that vesnarinone stimulates the production of TGF-P1 protein in TYS cells (Sato et al, 1997) . Therefore, we concluded that, at least in our human cell system, the expression of TSC-22 mRNA was slightly enhanced by vesnarinone in a few hours via its direct action and was apparently induced after 24 h, probably mediated by the production of other proteins, such as TGF-3.
Recently, we have reported that TYS cells contain the mutated pS3 gene and that both vesnarinone and TGF-5 1 enhanced the expression of p21 4'afl mRNA and its protein (Sato et al, 1997) . We therefore attempted to clarify the association of TSC-22 in the induction of p21l"afl in TYS cells. However, vesnarinone induced p21lwafl mRNA without any protein synthesis (Fig. 5) , and treatment with antisense oligonucleotide against TSC-22 mRNA did not affect the induction of p21 wafl mRNA by vesnarinone (data not shown). Chin et al (1996) reported that p2lwafJ was induced as an immediate-early gene in A431 cells by EGFR-STAT1 system. Thus, p21aafl was induced like an immediate-early gene in TYS cells as well, and TSC-22 may not lie upstream of p2hwafl in an antiproliferative pathway of vesnarinone.
As Shibanuma et al (1992) and Hamil and Hall (1994) previously mentioned in their papers about mouse and rat TSC-22 protein, human TSC-22 protein is also lacking the basic region at the N-terminus of the leucine zipper domain. Thus, human TSC-22 may interact with basic leucine zipper transcriptional factors and may act as a dominant-negative regulator, like CHOP (Ron and Habener, 1992) or IP-1 (Auwerx and Sassone-Corsi, 1991) . CHOP is a homologue of the C/EBP family of transcriptional factors and is also known as GADD (growth arrest and DNA damage) 153 (Fomace et al, 1989; Park et al, 1992) ; it acts as a dominant negative inhibitor of C/EBP (Ron and Habener, 1992; Barone et al, 1994a) . Expression of the CHOP (GADD153) gene is induced by several agents that cause growth arrest or DNA damage (Fomace et al, 1989) . Additionally, a dominant-negative regulator, Id, is a helix-loop-helix protein lacking the basic DNA-binding region, and is well studied in regulating cell growth and differentiation (Benezra et al, 1990) . Ids (Idl, Id2, 1d3 and Id4) specifically bind to the basic helix-loop-helix proteins, such as MyoD, E2A, E12, and E47, and inhibit their ability to bind DNA (Riechmann et al, 1994) . Ids regulate differentiation in several cellular systems, including myogenesis (Benezra et al, 1990; Kurabayashi et al, 1994) , neurogenesis (Nagata and Tadokoro, 1994) and haematogenesis (Sun, 1994) and cell growth (Barone et al, 1994b ).
Currently, we are investigating the tumour-suppressor function and differentiation-and apoptosis-inducing capability of TSC-22 in human salivary gland cancer cells, and are looking for the target proteins of TSC-22 by the yeast two-hybrid screening system. Futhermore, we are investigating the expression of TSC-22 in human salivary gland cancer tissue before treatment and the alteration of TSC-22 expression during treatment, and trying to use TSC-22 as a sensitivity marker or a prognostic marker for vesnarinone treatment.
